Risk and Benefit of Antiplatelet Therapy in COVID-19 Patients with Cancer and Thrombocytopenia: Letter to the Editor.
Saved in:
| Title: | Risk and Benefit of Antiplatelet Therapy in COVID-19 Patients with Cancer and Thrombocytopenia: Letter to the Editor. |
|---|---|
| Authors: | Nourmohammadi H; Department of Internal Medicine, School of Medicine, Shahid Mostafa Khomaeini Hospital, Ilam University of Medical sciences, Ilam, Iran., Azami G; Clinical Research Development Unit, Shahid Mostafa Khomeini Hospital, Ilam University of Medical Sciences, Ilam, Iran., Taghinezhad F; Clinical Research Development Unit, Shahid Mostafa Khomeini Hospital, Ilam University of Medical Sciences, Ilam, Iran., Shafiei E; Clinical Research Development Unit, Shahid Mostafa Khomeini Hospital, Ilam University of Medical Sciences, Ilam, Iran. |
| Source: | Cancer investigation [Cancer Invest] 2021 Mar; Vol. 39 (3), pp. 217-218. Date of Electronic Publication: 2021 Jan 14. |
| Publication Type: | Letter |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 8307154 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1532-4192 (Electronic) Linking ISSN: 07357907 NLM ISO Abbreviation: Cancer Invest Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
